Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia

Al-Azhar University306 enrolled

Overview

The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

306

Conditions

BPH With Other Lower Urinary Tract Symptoms

Interventions

TadalafilDRUG

tadalafil 2.5 mg, 5 mg

Eligibility

Sex: MALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged ≥ 45 years and sexually active with symptomatic benign prostatic hyperplasia (no hospitalization 3 months prior to start of treatment). Exclusion Criteria: * 1\. Patients with bladder or prostate malignancy. 2. A history of lower urinary tract surgery. 3. History of catheterization. 4. Urinary retention. 5. Urinary tract infection. 6. Stone disease. 7. Any neurological disease.

Locations (1)

outpatient clinic of the urology department at AlZahraa University Hospital, Al-Azhar University, Faculty of Medicine for Girls.

Cairo, Egypt

Outcomes

Primary Outcomes

Evaluation of International prostate symptom score (IPSS)/quality of life (QoL).

Time frame: 3 months compared to baseline

Evaluation of International index of erectile function (IIEF).

Time frame: 3 months compared to baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.